Elsevier

Gynecologic Oncology

Volume 100, Issue 2, February 2006, Pages 344-348
Gynecologic Oncology

Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer

https://doi.org/10.1016/j.ygyno.2005.08.036Get rights and content

Abstract

Objective.

To determine if the need to perform splenectomy due to metastatic disease in the context of complete primary cytoreduction for ovarian cancer diminishes the prognosis for survival.

Methods.

Between 1990 and 2004, 356 stage IIIC epithelial ovarian cancer patients underwent resection of all visible disease before systemic platinum-based combination chemotherapy. Forty-nine (13.8%) required a splenectomy due to metastatic disease. Survival was analyzed (log rank) on the basis of whether splenectomy was necessary. The frequency of performing other procedures, operative time, blood loss, transfusion rate, and hospitalization, was compared (Chi-square test; discrete and binomial data, t test; continuous data) on the basis of whether a splenectomy was required.

Results.

Survival was not influenced (log rank) by the requirement of splenectomy (required; median 56.4 months, estimated 5-year survival of 48% vs. not required; median 76.8 months, estimated 5-year survival of 58% P = 0.4). The splenectomy subgroup more commonly required en-bloc resection of reproductive organs with rectosigmoid (89.8% vs. 55.7%, P < 0.001), diaphragm stripping (63.3% vs. 33.6%, < 0.001)), full-thickness diaphragm resection (28.6% vs. 9.4%, P < 0.001), and resection of grossly positive retroperitoneal nodes (67.3% vs. 46.3%, P = 0.006). The splenectomy group had a longer operative time (238 min vs. 192 min, P = 0.004), estimated blood loss (1663 ml vs. 1167 ml, P = 0.001), transfusion rate (5.3 units prbc vs. 3.2 units prbc, P = 0.002), and hospitalization (16.1 vs. 12.2 days P = 0.001).

Conclusions.

The need for splenectomy to achieve complete cytoreduction is a reflection of advanced disease but is not a manifestation of tumor biology precluding long-term survival.

Introduction

Numerous reports have demonstrated the completeness of primary cytoreductive operations for advanced epithelial ovarian cancer to correlate with the prognosis for survival [1], [2], [3], [4], [5], [6], [7]. However, it has been suggested that a widespread upper abdominal tumor burden reflects “biologically aggressive” disease and that requirement of extensive as opposed to minimal upper abdominal operations to attain a visibly disease-free cytoreductive outcome may diminish or preclude the possibility of long-term survival [8], [9], [10], [11], [12]. Hence, the extent to which the natural history of advanced stage epithelial ovarian cancer can be altered if multiple upper abdominal procedures are necessary to accomplish “optimal” or complete cytoreduction remains somewhat controversial. The need to perform splenectomy in particular has been suggested to reflect a disease that is “biologically aggressive”, and the appropriateness of splenectomy in the context of primary cytoreductive operations has been questioned [11], [12]. In this series, we analyze whether the necessity to perform a splenectomy to achieve complete cytoreduction for stage IIIC epithelial ovarian cancer, due to splenic involvement with metastatic disease, increases morbidity and diminishes the probability of survival.

Section snippets

Methods and materials

Between 1990 and June 2004, 404 patients with stage IIIC epithelial ovarian cancer underwent primary cytoreductive surgery by members of the Encino–Tarzana division of the Woman's Cancer Center, of which 356 (88.1%) were cytoreduced to a visibly disease-free outcome. Of those completely cytoreduced, 49 (13.8%) required a splenectomy to accomplish complete cytoreduction in the context of their procedures. The extent of disease present before cytoreduction, morbidity, and subsequent survival of

Results

Within the cohort, the subgroup requiring a splenectomy was significantly older, had more extensive disease by multiple criteria, and required several procedures with a greater frequency (Table 1). The total operative time, estimated blood loss, units of blood transfused, and hospital stay were greater for patients who had a splenectomy, although an equivalent fraction were treated with chemotherapy before discharge (Table 2). Patients requiring splenectomy had an insignificant trend to more

Discussion

Median and long-term survival for patients with advanced stage epithelial ovarian cancer have been consistently reported to correlate with the completeness of primary cytoreductive surgery [1], [2], [3], [4], [5], [6], [7]. Nevertheless, relative influences of treatment strategy and “innate biological properties” of disease on the prognosis for long-term survival or cure remain somewhat controversial. It has been proposed that “optimal” and complete cytoreduction may be achievable due to

References (38)

Cited by (78)

  • Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes

    2022, Gynecologic Oncology
    Citation Excerpt :

    Further, there were no 30-day mortalities, and the rates of dead from disease, PFS, and OS were comparable between groups. Prior case series found a 30-day mortality rate after splenectomy to range from 0 to 8.8% [8–10,13]. Magtibay et al. had the largest series of patients undergoing splenectomy at 112 and reported a 5% mortality rate; however, they did not routinely use prophylactic anticoagulation and two of the six in their series who died succumbed to pulmonary embolism.

  • Radical Upper Abdominal Surgery

    2018, Principles of Gynecologic Oncology Surgery
  • Porta hepatis peritonectomy and hepato–celiac lymphadenectomy in patients with stage IIIC–IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes

    2016, Gynecologic Oncology
    Citation Excerpt :

    The majority of ovarian cancers present in advanced stages and are treated by debulking surgery and platinum based chemotherapy. Several retrospective and prospective studies confirmed improved survival in patients who have complete resection (CR) defined as no visible residual disease [3–10]. To achieve CR, extensive upper abdominal procedures are warranted.

  • Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer

    2015, Gynecologic Oncology
    Citation Excerpt :

    In order to achieve optimal surgical outcomes, primary debulking surgery is often lengthy and complex, requiring bowel resection and/or aggressive upper abdominal surgery [5]. Such extensive procedures are commonly associated with significant perioperative complications [6–11]. Given this risk, neoadjuvant chemotherapy followed by interval debulking is offered by certain providers to patients who are poor operative candidates due to age and/or medical comorbidity [12–15].

  • Splenectomy in epithelial ovarian cancer surgery

    2023, International Journal of Gynecological Cancer
View all citing articles on Scopus
View full text